Výsledky vyhledávání - "W. P. Maksymowych"

POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY

Autor: A. Deodhar, D. Van der Heijde, L. S. Gensler, H. Xu, K. Gaffney, H. Dobashi, W. P. Maksymowych, M. Rudwaleit, M. Magrey, D. Elewaut, M. Oortgiesen, C. Fleurinck, A. Ellis, T. Vaux, J. Smith, X. Baraliakos

Publikováno v: Annals of the Rheumatic Diseases. 81:772-773

BackgroundBimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ has shown rapid and sustained efficacy and was well tolerated up to 156 weeks (wks) in a phase 2b study in patients (pts) with activ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce61cbe31dccad4b60c3e3bdaa81490e
https://doi.org/10.1136/annrheumdis-2022-eular.2416

Zobrazit plný text záznamu

POS0341 CONSENSUS-DRIVEN DEFINITION FOR UNEQUIVOCAL SACROILIITIS ON RADIOGRAPHS IN JUVENILE SPONDYLOARTHRITIS

Autor: P. F. Weiss, T. G. Brandon, R. G. Lambert, D. M. Biko, N. A. Chauvin, M. L. Francavilla, N. Herregods, A. M. Hendry, W. P. Maksymowych

Publikováno v: Annals of the Rheumatic Diseases. 81:423-424

BackgroundRadiographs are not a sensitive or reliable imaging tool for detection of early sacroiliitis in juvenile spondyloarthritis (JSpA). However, radiographs are still commonly performed in some areas due to difficulty in accessing MRI. As such,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7b3180c886984a904792aa504520739f
https://doi.org/10.1136/annrheumdis-2022-eular.3727

Zobrazit plný text záznamu

POS0173 DATA-DRIVEN MRI DEFINITIONS FOR ACTIVE AND STRUCTURAL SACROILIAC JOINT LESIONS IN JUVENILE SPONDYLOARTHRITIS TYPICAL OF AXIAL DISEASE

Publikováno v: Annals of the Rheumatic Diseases. 81:316-317

BackgroundFor classification in juvenile spondyloarthritis (JSpA), it is important to develop cut-offs for active and structural lesions typical of axial disease on MRI that are readily and consistently interpreted. Since the maturing sacroiliac join

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::778f05a6e0f4f5d39496bdabcb69af82
https://doi.org/10.1136/annrheumdis-2022-eular.741

Zobrazit plný text záznamu

POS1259 AXIAL SPONDYLOARTHRITIS, AGE AND MALE GENDER IMPACT COVID VACCINATION AEs MORE THAN RHEUMATOID ARTHRITIS

Autor: S. Keeling, B. Pan, E. Hutchings, S. Wichuk, M. Osman, A. Singh, A. Sonpar, I. Swartz, W. P. Maksymowych

Publikováno v: Annals of the Rheumatic Diseases. 81:965-966

BackgroundRheumatologists recommend vaccination in rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA) patients, but there are few studies on the occurrence of adverse events (AEs), particularly worsening disease related activity and unrela

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c2fcde9b4201985725a56e583b104a88
https://doi.org/10.1136/annrheumdis-2022-eular.4156

Zobrazit plný text záznamu

OP0229 OSTEOARTHRITIS OF THE KNEE, INFLAMMATION, AND THE EFFECT OF ADALIMUMAB (OKINADA): A RANDOMIZED PLACEBO-CONTROLLED TRIAL

Autor: W. P. Maksymowych, L. Bessette, R. G. Lambert, A. Carapellucci, C. T. Appleton

Publikováno v: Annals of the Rheumatic Diseases. 81:151-152

BackgroundCytokines such as tumor necrosis factor (TNFα) have been shown to elicit inflammatory and catabolic events in the joints of patients with osteoarthritis. Recent RCTs demonstrated that TNFα inhibition has no effect on pain and MRI-detected

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c29168a65b57098e25a73e0de9c10722
https://doi.org/10.1136/annrheumdis-2022-eular.3422

Zobrazit plný text záznamu

OP0016 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL

Autor: A. Deodhar, F. Van den Bosch, D. Poddubnyy, W. P. Maksymowych, D. Van der Heijde, T. H. Kim, M. Kishimoto, Y. Duan, Y. Li, A. Pangan, P. Wung, I. H. Song

Publikováno v: Annals of the Rheumatic Diseases. 81:9-10

BackgroundJanus kinase (JAK) inhibitors have been recognized as a potential therapeutic option in ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA).1 Upadacitinib (UPA), a JAK inhibitor, has demonstrated effica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d2805b1efc445075ad50e6617beffb2
https://doi.org/10.1136/annrheumdis-2022-eular.2534

Zobrazit plný text záznamu

POS0995 VALIDATION OF THE SPARCC MRI-RETIC E-TOOL FOR INCREASING SCORING PROFICIENCY OF MRI LESIONS IN AXIAL SPONDYLOARTHRITIS

Publikováno v: Annals of the Rheumatic Diseases. 81:805.2-806

BackgroundThe web-based Spondyloarthritis Research Consortium of Canada (SPARCC) real-time iterative calibration (RETIC) modules for scoring MRI lesions in axial spondyloarthritis (axSpA) have been created by SPARCC developers to enable remote traini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6c91d007020f5334fba453f9a5f8332e
https://doi.org/10.1136/annrheumdis-2022-eular.4007

Zobrazit plný text záznamu

POS1258 LESS THAN EXPECTED IMPACT OF RHEUMATOID ARTHRITIS AND AXIAL SPONDYLOARTHRITIS DISEASE ON COVID SEVERITY

Autor: S. Keeling, B. Pan, E. Hutchings, S. Wichuk, M. Osman, A. Singh, A. Sonpar, I. Swartz, W. P. Maksymowych

Publikováno v: Annals of the Rheumatic Diseases. 81:964.2-965

BackgroundThroughout the pandemic, there has been ongoing concern that people with autoimmune diseases such as rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA) will have more severe COVID-19 disease due to immune dysfunction associated w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::72ab8c8de85baac4fe8a5d0a0d0608c3
https://doi.org/10.1136/annrheumdis-2022-eular.4152

Zobrazit plný text záznamu

POS0301 STRUCTURAL OUTCOMES IN THE SACROILIAC JOINT AFTER IXEKIZUMAB TREATMENT FOR 16 WEEKS IN PATIENTS WITH ACTIVE NON‑RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY GENDER, HLA-B27, AND BASELINE MRI INFLAMMATION

Autor: W. P. Maksymowych, X. Baraliakos, R. G. Lambert, R. B. M. Landewé, D. Sandoval, H. Carlier, J. Lisse, X. LI, M. Hojnik, M. Østergaard

Publikováno v: Annals of the Rheumatic Diseases. 81:399.1-399

BackgroundIxekizumab (IXE) has demonstrated clinical efficacy in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) together with significant repair of structural lesions in the sacroiliac joint (SIJ) on MRI. There is, however,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1c615bbe8039a6f27ee5b37223c3c94a
https://doi.org/10.1136/annrheumdis-2022-eular.2322

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání